公开(公告)号：US20100056439A1

公开(公告)日：2010-03-04

申请号：US12086020

申请日：2006-12-05

Applicant: Roland Beckmann ,  Rudolf M T De Wildt ,  Steve Holmes ,  Olga Ignatovich ,  Laurent S Jespers ,  Haiqun Liu ,  Malgorzata Pupecka ,  Armin Sepp ,  Michael Steward

Inventor： Roland Beckmann ,  Rudolf M T De Wildt ,  Steve Holmes ,  Olga Ignatovich ,  Laurent S Jespers ,  Haiqun Liu ,  Malgorzata Pupecka ,  Armin Sepp ,  Michael Steward

IPC: A61K38/16 ,  C07K14/00 ,  C07K16/00 ,  C07K14/765 ,  C07H21/00 ,  C12N15/63 ,  C12N1/00 ,  C12P21/00 ,  A61P35/00

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/31 ,  C07K2317/569

Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.

Abstract translation: 公开了对血管内皮生长因子（VEGF），表皮生长因子受体（EGFR）或VEGF和EGFR具有结合特异性的配体。 还公开了使用这些配体的方法。 特别地，描述了这些配体用于癌症治疗的用途。

公开(公告)号：US20090258012A1

公开(公告)日：2009-10-15

申请号：US12409617

申请日：2009-03-24

Applicant: Olga Ignatovich ,  Rudolf Maria Theodora de Wildt ,  Benjamin Woolven ,  Steven Grant ,  Philip C. Jones ,  Amrik Basran ,  Neil Brewis

Inventor： Olga Ignatovich ,  Rudolf Maria Theodora de Wildt ,  Benjamin Woolven ,  Steven Grant ,  Philip C. Jones ,  Amrik Basran ,  Neil Brewis

IPC: A61K39/395 ,  A61P19/02

CPC classification number: C07K16/468 ,  A61K47/6879 ,  C07K16/005 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K16/30 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00

Abstract: The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders.

Abstract translation: 本发明涉及用于治疗炎症性疾病的组合物和方法。 更具体地，本发明涉及抗体组合物及其在治疗炎症性疾病中的用途。

公开(公告)号：US20090081233A1

公开(公告)日：2009-03-26

申请号：US12217884

申请日：2008-07-09

Applicant: Olga Ignatovich ,  Steve Holmes ,  Roland Beckmann ,  Rudolf M.T. de Wildt ,  Armin Sepp

Inventor： Olga Ignatovich ,  Steve Holmes ,  Roland Beckmann ,  Rudolf M.T. de Wildt ,  Armin Sepp

IPC: A61K39/395 ,  C07K16/00 ,  A61P35/00

CPC classification number: C07K16/22 ,  A61K47/6845 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/241 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/00

Abstract: Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described.

Abstract translation: 公开了对血管内皮生长因子（VEGF），表皮生长因子受体（EGFR）或VEGF和EGFR具有结合特异性的配体。 还公开了使用这些配体的方法。 特别地，描述了这些配体用于癌症治疗的用途。

公开(公告)号：US20060280734A1

公开(公告)日：2006-12-14

申请号：US11165672

申请日：2005-06-24

Applicant: Gregory Winter ,  Ian Tomlinson ,  Olga Ignatovich

Inventor： Gregory Winter ,  Ian Tomlinson ,  Olga Ignatovich

IPC: A61K39/395 ,  C07K16/44 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06

CPC classification number: C07K16/005

Abstract: The present invention relates to a method for the generation of immunoglobulin molecules of predetermined specificity. In particular, the invention relates to a method for the retargeting of the epitope binding specificity of one or more antibodies using single variable domains which exhibit a dominant epitope binding specificity.

Abstract translation: 本发明涉及产生具有预定特异性的免疫球蛋白分子的方法。 特别地，本发明涉及使用显示优势表位结合特异性的单个可变结构域重定向一种或多种抗体的表位结合特异性的方法。

公开(公告)号：US20060106203A1

公开(公告)日：2006-05-18

申请号：US11023959

申请日：2004-12-28

Applicant: Greg Winter ,  Ian Tomlinson ,  Olga Ignatovich ,  Lucy Holt ,  Elena De Angelis ,  Philip Jones

Inventor： Greg Winter ,  Ian Tomlinson ,  Olga Ignatovich ,  Lucy Holt ,  Elena De Angelis ,  Philip Jones

IPC: C07K16/44 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06

CPC classification number: C07K16/18 ,  C07K16/241 ,  C07K16/2875 ,  C07K16/2878 ,  C07K16/40 ,  C07K16/42 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/92 ,  C07K2318/20

Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

公开(公告)号：US20060002935A1

公开(公告)日：2006-01-05

申请号：US10985847

申请日：2004-11-10

Applicant: Neil Brewis ,  Benjamin Woolven ,  Steve Holmes ,  Ian Tomlinson

Inventor： Neil Brewis ,  Benjamin Woolven ,  Steve Holmes ,  Ian Tomlinson

IPC: A61K39/395 ,  C07K16/24

CPC classification number: C07K16/18 ,  A61K47/60 ,  A61K2039/505 ,  C07K16/241 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/40 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C12N2799/021

Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides antagonists of Tumor Necrosis Factor Receptor 1, such as ligands that contain an immunoglobulin single variable domain or domain antibody (dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.

Abstract translation: 本发明提供治疗炎性疾病（例如慢性炎性疾病）的方法，其包括施用肿瘤坏死因子受体1拮抗剂。本发明还提供了肿瘤坏死因子受体1的拮抗剂，例如含有免疫球蛋白单可变结构域或结构域的配体 结合肿瘤坏死因子受体1的抗体（dAb）单体和使用配体的方法。 还提供了编码配体的核酸，重组宿主细胞和制备配体的方法。

公开(公告)号：US20040038291A2

公开(公告)日：2004-02-26

申请号：US09968561

申请日：2001-10-01

Applicant: Domantis Limited

Inventor： Ian Tomlinson ,  Greg Winter

IPC: G01N033/53 ,  C07K016/00

CPC classification number: C07K1/047 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/7051 ,  C07K16/00 ,  C07K16/005 ,  C07K2317/21 ,  C07K2317/622 ,  C12N15/1037 ,  C40B30/04 ,  C40B40/02 ,  G01N33/6845 ,  G01N33/6854

Abstract: Abstract of the Disclosure The present invention relates to methods for selecting repertoires of polypeptides using generic and target ligands. In particular, the invention relates to a library comprising a repertoire of polypeptides of the immunoglobulin superfamily, wherein the members of the repertoire have a known main chain conformation.

Abstract translation: 公开内容摘要本发明涉及使用通用和靶配体选择多肽序列的方法。 特别地，本发明涉及包含免疫球蛋白超家族多肽的所有组成成分的文库，其中所述谱的成员具有已知的主链构象。

公开(公告)号：US11180567B2

公开(公告)日：2021-11-23

申请号：US16218077

申请日：2018-12-12

Applicant: Bristol-Myers Squibb Company ,  Domantis Limited

Inventor： Steven G. Nadler ,  James K. Tamura ,  Laura Price ,  Robert P. Rehfuss ,  Suzanne J. Suchard ,  Anish Suri ,  James William Bryson ,  Aaron Yamniuk ,  Steven Grant ,  Olga Ignatovich ,  Philip Drew

IPC: A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  C07K16/46 ,  C07K16/18 ,  A61K39/00 ,  A61K38/00

Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

公开(公告)号：US10196451B2

公开(公告)日：2019-02-05

申请号：US15668305

申请日：2017-08-03

Applicant: Bristol-Myers Squibb Company ,  Domantis Limited

Inventor： Steven G. Nadler ,  James K. Tamura ,  Laura Price ,  Robert P. Rehfuss ,  Suzanne J. Suchard ,  Anish Suri ,  James William Bryson ,  Aaron Yamniuk ,  Steven Grant ,  Olga Ignatovich ,  Philip Drew

IPC: A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  C07K16/18 ,  A61K39/00 ,  A61K38/00

Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

公开(公告)号：US09765150B2

公开(公告)日：2017-09-19

申请号：US14950949

申请日：2015-11-24

Applicant: Bristol-Myers Squibb Company ,  Domantis Limited

Inventor： Steven G. Nadler ,  James K. Tamura ,  Laura Price ,  Robert P. Rehfuss ,  Suzanne J. Suchard ,  Anish Suri ,  James William Bryson ,  Aaron Yamniuk ,  Steven Grant ,  Olga Ignatovich ,  Philip Drew

IPC: A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  C07K16/46 ,  C07K16/18 ,  A61K39/00 ,  A61K38/00

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K16/283 ,  C07K16/2833 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.